Explore how Low Dose Naltrexone may target inflammaging and support healthspan, based on real-world findings from 5,500 participants.
Tag: agelessrx trial
Explore how Microdosing Semaglutide may support metabolic health, inflammation, and longevity, including what our GLP-1 trial is studying.
Curious about the SF-36 quality of life study? Discover what this validated health survey measures and what our longevity research found.
Fat intake, gut microbiome composition, and enzyme activity may all influence Rapamycin absorption. See what our study revealed.
Explore PEARL trial findings on Rapamycin, Low Dose Naltrexone, and bone density, including a notable case report, potential mechanisms, safety considerations, and the need for larger clinical studies.
Low Dose Naltrexone and NAD+ were tested together for Long COVID fatigue in our trial. Learn what the results showed and why the combination worked.
Our Research Team tracked Acarbose as a longevity intervention in a pilot trial. See biomarker findings, glucose data, and tolerability results.
A closer look at our Canagliflozin pilot trial, including the study design, metabolic findings, glucose response, and tolerability in healthy adults.
AgelessRx shares early XPRIZE Healthspan semifinal results and what they suggest about the future of personalized longevity medicine.
AgelessRx is a Semi-Finalist in the landmark XPRIZE Healthspan competition, a milestone that may propel longevity solutions to the spotlight.
AgelessRx is now a Certified Vitalist Organization, advancing the longevity movement and fighting aging globally. Learn more about the certification and what it means for the longevity movement.
AgelessRx has partnered with Longevity Labs on a descriptive study that has shown positive results for quality-of-life outcomes.
Learn about AgelessRx’s recent gift to the Michigan Medicine Division of Geriatric and Palliative Medicine Geriatrics Center.
Check out this video webinar series about a new AgelessRx sponsored study on the use of Rapamycin in longevity treatment.
AgelessRx is working to get more traction on clinical and scientific studies that can help us learn more about how LDN may impact longevity.
AgelessRx has started recruiting participants to our clinical trial PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity).
Former ARX CMO Dr. Zalzala introduces new post-COVID-19 pilot study and shares how LDN and NAD+ may help with post-COVID-19 Syndrome.
Chief Executive Officer, Anar Isman, recently sat down with Longevity Technology to talk about ARX’s noteworthy Rapamycin clinical trial.